Patent Yard Sign in
Expired Canadian patentCanada

Selecting, compounding and testing antibodies for cancer diagnosis and therapy

CA 1305919 C · Owner: Rhomed Incorporated · Inventors: Rhodes, Buck A.

CIPO record

Overview

Drawings and full text

Its claims, description and drawings are in the Canadian Patents Database.

Open the CIPO record

Abstract From the Canadian patent

A method and an apparatus for selecting monoclonal antibodies or antibody fragments for use in preparing drugs for cancer detection or therapy, and a kit for compounding selected radiolabeled monoclonal antibodies or antibody fragments for in vivo cancer diagnosis and therapy. The kit provides reagents for: (1) the selection of monoclonal antibodies or antibody fragments which are specific to a tumor specimen; (2) compounding the selected antibodies with a radionuclide material; and (3) quality control testing of the resulting compound. In the method of the invention, multiple aliquots of tumor biopsy material are fixed onto separate test areas of an apparatus which permits reaction with a …

Read the whole patent

Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.

Why it's free to use

  • Granted August 4, 1992. A Canadian patent filed before October 1, 1989 lasted 17 years from grant, so its term ended August 4, 2009.
  • We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
FiledJanuary 23, 1987
GrantedAugust 4, 1992
Term endedAugust 4, 2009
Patent numberCA 1305919 C
Classification (IPC)G01N33/53 +2 more

Timeline

Timeline From CIPO dates

19881991199419972000200320062009Application filedJan 23, 1987Patent grantedAug 4, 1992Term endedAug 4, 2009

Sources & verification

Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.